Vivos therapeutics reports full year 2024 financial results and provides operational update

Year over year product revenue increased 26% operating expenses declined 21% and year over year operating loss decreased 35% management to host conference call today at 5:00 pm et littleton, colo., march 31, 2025 (globe newswire) -- vivos therapeutics, inc. (“vivos” or the “company'') (nasdaq: vvos), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (osa in adults) and moderate to severe osa in children ages 6 - 17), today reported financial results and operating highlights for the full year ended december 31, 2024.
VVOS Ratings Summary
VVOS Quant Ranking